维普期刊资源整合服务平台（V6.5）

55篇 您的检索式：作者名="Alagona"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Effects of n -3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease显示文摘	L. Spadaro O. Magliocco D. Spampinato S. Piro C. Oliveri C. Alagona G. Papa A.M. Rabuazzo F. Purrello	2007	Digestive and Liver Disease2007，，3：	2
2	A new force field for molecular mechanical stimulation of nucleic acids and proteins显示文摘	Weiner SJ Kollman PA Case DA Singh UC Ghio C Alagona G	1984	J Am Chem Soc1984，106，3：	1
3	Beyond LDL cholesterol : the role of elevated triglyc- erides and low HDL cholesterol in residual CVD risk remaining af- ter statin therapy显示文摘	Alagona P Jr	2009	Am J Manag Care2009，15，3：	1
4	Post-stroke reorganization of hand motor area:a 1-year prospective follow-up with focal transcranial magnetic stimulation显示文摘	Delvaux V Alagona G Gerard P	2003	Clin Neurophysiol2003，114，7：	1
5	Helicobacter pylori and Alzheimer's disease : a possible link 显示文摘	Malaguarnera M Bella R Alagona G	2004	Eur J In- tern Med2004，15，6：	1
6	Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes显示文摘	Alagona PJr	2010	J Invasive Cardiol2010，22，1：	1
7	Post-stroke reorganization of hand motor area : a 1-year prospective follow- up with focal transcranial magnetic stimulation 显示文摘	Delvaux V Alagona G Gerard P	2003	Clin Neurophysiol2003，114，7：	1
8	Nuclear magnetic resonance imaging in a patient with a DDD pacemaker显示文摘	Alagona P Jr Toole J C Maniscalco B S	1989	Pacing Clin Electrophysiol1989，12，4：	1
9	Equivalent efficy of a time-release form of niacin(niaspan) given once-night versus plain niacin in the management of hyperlipidemia显示文摘	Knopp RH Alagona P Davidson M	1998	Metabolism1998，47，9：	1
10	Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia显示文摘	Alagona P Jr Capuzzi DM	2000	Am J Cardiol2000，85，9：	1
11	Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia显示文摘	Goldberg A Alagona P Capuzzi D	2000	Am J Cardiol2000，85，：	1
12	Fenofibric acid: A new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia 显示文摘	Alagona PJ	2010	Vasc Health Risk Manag2010，25，6：	1
13	Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy 显示文摘	Alagona P	2009	Am J Manag Care2009，15，3：	1
14	Muhiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia显示文摘	Goldberg A Alagona P J Capuzzi D M	2000	Am J Cardiol2000，85，9：	1
15	Low HDL cholesterol concentrafion is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterol显示文摘	Alagona C Soro A Westerbacka J	2003	Eur J Clin Invest2003，33，：	1
16	Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy 显示文摘	ALAGONA P	2009	Am J Manag Care2009，15，3：	1
17	The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology显示文摘	Laslett LJ Alagona P Clark BA	2012	J Am Coll Cardiol2012，60，25：	1
18	Beyond LDL cholesterol:the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy显示文摘	Alagona P	2009	Am J Manag Care2009，15，3：	1
19	Beyond LDL cholesterol:the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy显示文摘	Alagona P	2009	Am J Manag Care2009，15，3：	1
20	Beyond LDL cholesterol : the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining afer statin therapy 显示文摘	Peter Alagona Jr	2009	Am J Manag Care2009，15，：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示